KalVista Pharmaceuticals Ltd.

KalVista Pharmaceuticals Ltd. launched in August 2011 as a spin out of Vantia Therapeutics. KalVista acquired a portfolio of small-molecule plasma kallikrein inhibitors from Vantia's preclinical store. The compounds will be developed to treat diabetic macular edema, a condition that threatens the vision of up to a quarter of the world's 285 million diabetes sufferers.